Search Results
You are looking at 1 - 9 of 9 items for
- Author: D S Jessop x
- Refine by access: All content x
Department of Pyschopharmacology, H Lundbeck A/S, Copenhagen, Denmark
Search for other papers by S Hesketh in
Google Scholar
PubMed
Department of Pyschopharmacology, H Lundbeck A/S, Copenhagen, Denmark
Search for other papers by D S Jessop in
Google Scholar
PubMed
Department of Pyschopharmacology, H Lundbeck A/S, Copenhagen, Denmark
Search for other papers by S Hogg in
Google Scholar
PubMed
Department of Pyschopharmacology, H Lundbeck A/S, Copenhagen, Denmark
Search for other papers by M S Harbuz in
Google Scholar
PubMed
Serotonin re-uptake inhibitors (SSRIs) can affect the basal activity of the hypothalamic–pituitary–adrenal (HPA) axis in rats. A single injection of citalopram has been shown to stimulate the HPA axis while repeated administration leads to attenuation of the corticosterone response to the SSRI. The purpose of this work was to investigate the rodent HPA axis response to restraint stress, following acute and chronic treatment with the SSRI citalopram. We have demonstrated that a single injection of citalopram is able to prolong acute restraint-induced increases in plasma levels of corticosterone and adrenocorticotrophin (ACTH). This is possibly mediated by arginine vasopressin (AVP) in the parvocellular cells of the paraventricular nucleus (pPVN), as treatment with citalopram or restraint alone did not increase AVP mRNA in pPVN while the combination of treatments resulted in a significant increase in AVP mRNA in the pPVN. In contrast, the increase in corticotrophin-releasing factor (CRF) mRNA in the pPVN in response to acute restraint stress was not altered by citalopram. Oxytocin (OT) mRNA was also increased in the magnocellular PVN (mPVN) by the solo treatments of citalopram and restraint, and was not further enhanced by the dual treatment of restraint and citalopram. Chronic treatment with citalopram did not alter basal plasma levels of corticosterone or ACTH. However, the ACTH response to acute restraint was attenuated following chronic citalopram treatment. AVP mRNA in the pPVN was significantly elevated in response to chronic citalopram compared with saline controls suggesting an effect mediated through the AVP subset of pPVN neurones. The CRF mRNA response to acute restraint was not altered in rats treated chronically with citalopram. OT mRNA was not enhanced in the mPVN following chronic infusion of citalopram but was increased by acute restraint stress. We conclude from these data that both acute and chronic citalopram treatment has the potential to alter the rodent response to acute restraint stress. These effects appear to be regulated by the AVP-containing subset of CRF neurons in the pPVN and thus suggest that parvocellular AVP may have an important role in mediating the actions of SSRIs.
Search for other papers by P J Larsen in
Google Scholar
PubMed
Search for other papers by J D Mikkelsen in
Google Scholar
PubMed
Search for other papers by D Jessop in
Google Scholar
PubMed
Search for other papers by S L Lightman in
Google Scholar
PubMed
Search for other papers by H S Chowdrey in
Google Scholar
PubMed
Abstract
We have investigated the effects of monosodium glutamate (MSG) lesioning of the arcuate nucleus on both central and peripheral components of the hypothalamo-pituitary-adrenocortical (HPA) axis under basal conditions and under acute and chronic stress. Plasma ACTH levels were lower in MSG-lesioned rats (27 ± 7 pg/ml) compared with controls (71 ± 18 pg/ml) while corticosterone levels were elevated (523 ± 84 ng/ml compared with 176 ± 34 ng/ml). Quantititative in situ hybridization histochemistry revealed that corticotrophin-releasing factor mRNA levels in the medial parvocellular part of the hypothalamic paraventricular nucleus were significantly lower in MSG-treated rats. MSG lesioning resulted in an enhanced response of corticosterone to restraint stress (1309 ± 92 ng/ml compared with 628 ± 125 ng/ml in sham-lesioned animals), while ACTH responses to restraint stress in MSG-lesioned and sham-MSG groups were not significantly different (160 ± 24 pg/ml and 167 ± 24 pg/ml respectively). These data suggest that MSG-lesioned rats have an increased adrenocortical sensitivity. In rats subjected to the chronic osmotic stimulus of drinking 2% saline for 12 days, plasma ACTH levels were significantly reduced (15 ± 5 pg/ml) and the ACTH and corticosterone responses to restraint stress were eliminated. ACTH levels were also reduced in MSG-treated animals given 2% saline and the ACTH response to acute stress remained absent in these animals. However, a robust corticosterone response to restraint stress was observed in saline-treated MSG-lesioned rats. These data demonstrate that MSG lesioning results in elevated basal and stress-induced plasma corticosterone, and restores the adrenocortical response to stress which is absent in chronically osmotically stimulated rats. The evidence is consistent with the suggestion that MSG lesions a pathway involved in tonic inhibition of the HPA axis. In addition, the adrenocortical sensitivity to ACTH and other secretagogues may be increased in MSG-treated animals.
Journal of Endocrinology (1994) 141, 497–503
Search for other papers by D. S. Jessop in
Google Scholar
PubMed
Search for other papers by D. J. A. Eckland in
Google Scholar
PubMed
Search for other papers by K. Todd in
Google Scholar
PubMed
Search for other papers by S. L. Lightman in
Google Scholar
PubMed
ABSTRACT
We have detected significant amounts of corticotrophin-releasing factor-41 (CRF-41) in the rat hypothalamo-neurointermediate lobe system using a radioimmunoassay and reversed-phase high-performance liquid chromatography. Total amounts of CRF-41 in extracts of median eminence (ME), supraoptic nucleus (SON), paraventricular nucleus (PVN) and neurointermediate lobe (NIL) from control animals were 1076 ± 132, 196 ± 44, 22 ± 7 and 147 ± 50 fmol respectively (means ± s.e.m., n = 6). In animals given 340 mmol NaCl/l instead of tap water to drink for 12 days, no significant changes occurred in the CRF-41 content of the ME, SON or PVN, but CRF-41 content increased more than twofold in the NIL (362 ± 58 fmol). Plasma concentrations of CRF-41 and ACTH in control animals were 23 ± 6 and 51 ± 8 pmol/l respectively. After saline treatment no significant change in plasma CRF-41 was detected (20 ± 8 pmol/l) but concentrations of circulating ACTH were decreased (15 ± 2 pmol/l). The CRF-41 content of both the ME and the NIL was significantly depleted after intracerebroventricular injection of colchicine (414 ± 81 and 34 ± 7 fmol respectively). These data suggest that NIL CRF-41 is of hypothalamic origin and can be regulated by an osmotic stimulus.
Journal of Endocrinology (1989) 120, 119–124
Search for other papers by D. S. Jessop in
Google Scholar
PubMed
Search for other papers by H. S. Chowdrey in
Google Scholar
PubMed
Search for other papers by P. J. Larsen in
Google Scholar
PubMed
Search for other papers by S. L. Lightman in
Google Scholar
PubMed
Introduction
Substance P (SP) is a bit like the fifth man in British espionage – around for a long time but never named. Because this peptide was originally discovered during the search for acetylcholine (Von Euler & Gaddum, 1931) and, much later, isolated and sequenced by a group more interested in corticotrophin-releasing factor (Chang, Leeman & Niall, 1971), one could be forgiven for thinking that it was decreed to remain anonymous as punishment for obstructing more urgent research. The truth is, however, that so many actions have been ascribed to SP that no sufficiently dominant function has arisen to justify the appellation of a descriptive noun. The properties of vasodilation and smooth muscle contraction are well known (Iversen, Watson, Sandberg et al. 1985), and SP is also strongly implicated in the process of nociception (Iversen, 1982). In addition to these classically described functions, closer attention has been paid more recently
Search for other papers by G Aguilera in
Google Scholar
PubMed
Search for other papers by D S Jessop in
Google Scholar
PubMed
Search for other papers by M S Harbuz in
Google Scholar
PubMed
Search for other papers by A Kiss in
Google Scholar
PubMed
Search for other papers by S L Lightman in
Google Scholar
PubMed
Abstract
The expression of corticotropin releasing hormone (CRH) in the hypothalamic paraventricular nucleus (PVN) and CRH receptor mRNA in the PVN and anterior pituitary was studied during development of adjuvant-induced arthritis in Piebald–Viral–Glaxo rats, using in situ hybridization techniques. As previously shown with i.p. hypertonic saline injection, basal and immobilization stress-stimulated CRH mRNA levels in the PVN were significantly lower than in controls 14 days after adjuvant injection. However, 7 days after injection, preceding the onset of inflammation, the increase of CRH mRNA following immobilization was significantly higher than in control rats. In contrast to other chronic stress paradigms, inflammation stress failed to induce type-1 CRH receptor (CRH-R1) mRNA in the PVN, either at 7 days, or at 14 days after adjuvant injection, when inflammation is present. The ability of acute immobilization to induce CRH-R1 mRNA in the PVN was not affected 14 days after adjuvant injection but parallel to the CRH peptide mRNA response it was markedly potentiated at 7 days. Pro-opiomelanocorpin (POMC) mRNA levels in the anterior pituitary increased significantly 14 days after adjuvant injection, and they were unaffected by 1 h immobilization. While CRH binding in the pituitary decreased significantly 14 days after adjuvant injection, CRH-Rl mRNA was unchanged. This study shows biphasic hypothalamic responses to acute stress during development of adjuvant-induced arthritis, with enhanced CRH peptide and CRH-Rl mRNAs responses at 7 days, preceding the onset of inflammation, and blunted CRH mRNA responses at 14 days at the height of the inflammatory response. The lack of CRH receptor expression in the PVN in this model of chronic inflammation stress associated to low hypothalamic CRH peptide levels supports the view that positive feedback regulation by CRH is necessary to maintain enhanced CRH expression during chronic stress.
Journal of Endocrinology (1997) 153, 185–191
Search for other papers by D. S. Jessop in
Google Scholar
PubMed
Search for other papers by R. L. Patience in
Google Scholar
PubMed
Search for other papers by D. Cunnah in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
Degradation of tracer during a radioimmunoassay (RIA) can result in false-positive concentrations of immunoreactivity being reported in a biological sample. A technique has been developed using reversed-phase high-performance liquid chromatography (HPLC) to detect proteolytic degradation of corticotrophin-releasing factor-41 (CRF-41) during incubation with tissue extracts under RIA conditions. Human pancreatic tissue was extracted in HCl or urea and incubated with 125I-labelled CRF-41 at neutral pH for 18 h. When samples were analysed by HPLC and fractions counted for radioactivity, tracer was extensively degraded. Heating extracts at 85 °C or adding lima bean trypsin inhibitor to the medium prevented degradation. Pancreatic tissue extracted in HCl was analysed by gel filtration and HPLC, and fractions were subjected to RIA for CRF-41. A peak of immunoreactivity was detected by both chromatographic methods. However, when this material was incubated with tracer and analysed by HPLC, the tracer was degraded, indicating that proteolytic activity remained after acid extraction and two forms of chromatography.
J. Endocr. (1987) 114, 147–151
Search for other papers by D. Cunnah in
Google Scholar
PubMed
Search for other papers by D. S. Jessop in
Google Scholar
PubMed
Search for other papers by G. M. Besser in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
A radioimmunoassay was developed to measure corticotrophin-releasing factor (CRF-41) extracted from human plasma using Vycor glass. Assay sensitivity was 20 ng/l and intra- and interassay coefficients of variation were 10·2 and 11·4% respectively. The normal range of plasma CRF-41 was <20–110ng/l (n = 46). Plasma concentrations of CRF-41 in patients with Cushing's disease, Nelson's syndrome and Addison's disease were within the normal range. No correlation was found between CRF-41 and ACTH in these syndromes. Two patients with the ectopic ACTH syndrome had increased plasma concentrations of CRF-41. In normal subjects no changes in plasma CRF-41 occurred after insulin-induced hypoglycaemia, treatment with dexamethasone or feeding, and changes in the concentrations of CRF-41 did not reflect circadian changes in plasma concentrations of cortisol. Concentrations of immunoreactive CRF in plasma of women in the third trimester of pregnancy were increased (550–9300 ng/l) and gel filtration chromatography showed that this comprised CRF-41 and a higher molecular weight form. Reversed-phase high-performance liquid chromatography also revealed multiple peaks of immunoreactive CRF in extracts of plasma and placenta.
J. Endocr. (1987) 113, 123–131
Search for other papers by R H Straub in
Google Scholar
PubMed
Search for other papers by L B Tankó in
Google Scholar
PubMed
Search for other papers by C Christiansen in
Google Scholar
PubMed
Search for other papers by P J Larsen in
Google Scholar
PubMed
Search for other papers by D S Jessop in
Google Scholar
PubMed
The presence of peripheral fat mass (PFM) appears to counteract the atherogenic trends of central fat mass through mechanisms presently poorly understood. In elderly women with distinct forms of body fat distribution, we wanted to study whether physical activity and aortic calcification are related to plasma levels of cortisol, 17-α-hydroxyprogesterone (17-α-OHP), dehydroepiandrosterone (DHEA), androstenedione (ASD), and interleukin 6 (IL6) accomplishing an anti-atherogenic milieu. A total of 276 well-defined generally healthy women aged 60–85 years were included. Categorization of body fat distribution was based on the relative presence of central to PFM measured by dual-energy X-ray absorptiometry. Women meticulously reported weekly physical activity. Outcome measures were aortic calcification between lumbar vertebra L1 and L4, plasma levels of hormones, and IL6. In peripheral adipose women, plasma DHEA and ASD increased with the degree of physical activity. This was also mirrored in the ratios of cortisol/DHEA and cortisol/17-α-OHP. Peripheral adipose women with high DHEA relative to cortisol had less severe aortic calcification, and in the same group a higher level of physical activity was associated with lower levels of plasma IL6. In conclusion, this study demonstrates that high physical activity is associated with a high circulating androgen to cortisol ratio, low IL6, and less severe aortic calcification. Since androgens inhibit IL6 secretion, the activity-induced increase of these hormones might be an anti-atherogenic signal.
Search for other papers by D. S. Jessop in
Google Scholar
PubMed
Search for other papers by D. Cunnah in
Google Scholar
PubMed
Search for other papers by J. G. B. Millar in
Google Scholar
PubMed
Search for other papers by E. Neville in
Google Scholar
PubMed
Search for other papers by P. Coates in
Google Scholar
PubMed
Search for other papers by I. Doniach in
Google Scholar
PubMed
Search for other papers by G. M. Besser in
Google Scholar
PubMed
Search for other papers by L. H. Rees in
Google Scholar
PubMed
ABSTRACT
The case is described of a 61-year-old male who presented with hypertension and Cushing's syndrome which resolved on excision of a unilateral adrenal mass. Histology of the tumour revealed a benign phaeochromocytoma which immunostained for corticotrophin-releasing factor (CRF-41) but not for ACTH. Preoperative plasma concentrations of immunoreactive CRF-41 were increased, and gradients for both CRF-41 and ACTH were demonstrated across the tumour.
Post-operatively, CRF-41 was undetectable in plasma. The tumour contained high concentrations of immunoreactive CRF-41 which co-eluted with synthetic human CRF-41 on reversed-phase high-performance liquid chromatography. Tumour CRF-41 stimulated the release of ACTH in a dose-dependent manner from isolated rat anterior pituitary cells. We conclude that this tumour secreted CRF-41 and ACTH and had the capacity to produce ACTH-dependent Cushing's syndrome directly by secreting ACTH and indirectly by secreting CRF-41 to stimulate ACTH secretion from the anterior pituitary.
J. Endocr. (1987) 113, 133–138
